knowledge -WSS

knowledge

author：comprehensive 2025-09-29 13:09:48 - browse：3758

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Special counsel alerts court to Trump’s social media post

WSS

Surprise medical billing ban raises prices elsewhere

Calls for Trump's election interference trial to be televised part of long debate

Opioid cravings were reduced by anti

New CMS data security rules will hurt Medicare, Medicaid research

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

Medical mystery: When an infection after surgery isn’t what it seems

focus

knowledge

leisure time

Sports medicine is finally prioritizing gender equality

Opioid cravings were reduced by anti

Hollywood unions extend contract negotiations for actors

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Slain Parkland victim's father speaks out following reenactment

As demand for Covid shots wanes, Moderna seeks its next success

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

As demand for Covid shots wanes, Moderna seeks its next success

Obamacare plans could cover weight loss drugs

hotspot

In 'major milestone,' FDA approves first cell therapy for solid tumors

Secretariat’s lessons for human medicine

Weight loss drugs aren’t covered by Obamacare. That may change

New CMS data security rules will hurt Medicare, Medicaid research

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Elevance, SCAN deals highlight health insurer acquisition scrutiny

entertainment

entertainment

hotspot

focus